Low-molecular-weight heparins in the treatment of deep-vein thrombosis

Annals of Pharmacotherapy

Volumn 32, Issue 5, 1998, Pages

  Martineau, Pierre ^a,b   Tawil, Nadine ^c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Deep vein thrombosis; Low molecular weight heparins; Unfractionated heparin

Indexed keywords

DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

ANTICOAGULANT THERAPY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; HEPARINIZATION; HUMAN; IMPEDANCE PLETHYSMOGRAPHY; PHLEBOGRAPHY; PRIORITY JOURNAL; REVIEW;

BLOOD PLATELETS; CAPILLARY PERMEABILITY; DALTEPARIN; ENOXAPARIN; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NADROPARIN; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 15144346191     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.16450     Document Type: Review

References (49)

1. Zamorski MA, Opdycke RC. Advances in the prevention, diagnosis and treatment of deep venous thrombosis. Am Fam Physician 1993;47:457-69.
2. Silver D. An overview of venous thromboembolism prophylaxis. Am J Surg 1991;161:537-9.
3. Rooke TW, Osmundson PJ. Heparin and the in-hospital management of deep venous thrombosis: cost considerations. Mayo Clin Proc 1986;61: 198-204.
4. Papazian A, Hardy B. Deep vein thrombosis - diagnosis and management. On Contin Pract 1990;17(3):17-22.
5. Erdman SM, Rodvold KA, Friedenberg WR. Thromboembolic disorders. In: DiPiro JP, Talbert RL, Hayes PE, Yee GC, Matzke GR, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 2nd ed. Norwalk, CT: Appleton & Lange, 1993:312-35.
6. Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med 1981;94:439-44.
7. Kayser SR. Thrombosis. In: Young LY, Koda-Kimble MA, eds. Applied therapeutics: the clinical use of drugs. Vancouver, WA: Applied Therapeutics, 1995:12.7-11.
8. Baker WF, Bick RL. Deep vein thrombosis: diagnosis and management. Med Clin North Am 1994;78:685-713.
9. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1995;108(suppl 4):335S-51S.
10. Clagett GP, Anderson FA, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995;108(suppl 4):312S-34S.
11. Hull RD, Pineo GF. Therapeutic use of low molecular weight heparins: knowledge to date and their application to therapy. Semin Thromb Hemost 1994;20:339-44.
12. Hull RD, Pineo GF. Low molecular weight heparin treatment of venous thromboembolism. Prog Cardiovasc Dis 1994;37:71-8.
13. Cziraky MJ, Spinier SA. Low molecular weight heparins for the treatment of deep vein thrombosis. Clin Pharm 1993;12:892-9.
14. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79:1-17.
15. Barrowcliffe TW. Low molecular weight heparin(s). Br J Haematol 1995;90:1-7.
16. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108(suppl 4):258S-75S.
17. Friedel HA, Balfour JA. Tinzaparin: a review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. Drugs 1994;48:638-60.
18. Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 1990;40:498-530.
19. Buckley MM, Sorkin EM. Enoxaparin: a review of its pharmacology and clinical applications in the prevention of thromboembolic disorders in patients undergoing hip replacement. Drugs 1992;44:465-97.
20. Green D, Hirsh J, Heit J, Prins M, Davidson B, Lensing AWA. Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol Rev 1994;46:89-109.
21. Howard PA. Dalteparin: a low-molecular-weight heparin. Ann Pharmacother 1997;31:192-203.
22. Bratt G, Törnebohm E, Widlund L, Lockner D. Low molecular weight heparin (Kabi 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986;42: 613-20.
23. Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1992;22:359-74.
24. Collignon F, Frydman A, Caplain H, Ozoux ML, Le Roux Y, Bouthier J, et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995;73:630-40.
25. Samama MM. Contemporary laboratory monitoring of low molecular weight heparins. Clin Lab Med 1995;15:119-23.
26. Mätzsch T, Bergqvist D, Hedner U, Østergaard P. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost 1987;57:97-101.
27. Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin): results of a double-blind randomized study. Circulation 1989;80:935-40.
28. Holm HA, Ly B, Handeland GF, Abilgaard U, Arnesen KE, Gottschalk P, et al. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis 1986;16(suppl 2):30-7.
29. Lopaciuk S, Meissner AJ, Filipecki S, Zawilska K, Sowier J, Ciesielski L, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost 1992;68:14-8.
30. Heilmann JJ, Aiach M, Fiessinger JN, Vitoux JF, Derlon A, Grollier G, et al. Traitement des thromboses veineuses profondes constituées: étude comparative d'un fragment d'héparine de bas poids moléculaire (Fragmine) administrée par voie sous-cutanée et de l'héparine standard administrée par voie intraveineuse continue: étude multicentrique. Rev Med Interne 1989;10:375-81.
31. Bratt G, Åberg W, Johansson M, Törnebohm E, Granqvist S, Lockner D. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis. Thromb Haemost 1990;64:506-10.
32. Lindmarker P, Holmström M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thromb Haemost 1994;72:186-90.
33. Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal vein thrombosis. Arch Intern Med 1993;153:1541-6.
34. A Collaborative European Multicentre Study. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1991;65:251-6.
35. Prandoni P, Lensing AWA, Büller HR, Carta M, Cogo A, Vigo M, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep vein thrombosis. Lancet 1992; 339:441-5.
36. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992;326:975-82.
37. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996;334:677-81.
38. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, Van Der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home (published erratum appears in N Engl J Med 1997;337:1251). N Engl J Med 1996;334:682-7.
39. Fiessinger JN, Lopez-Fernandez M, Gatterer E, Granqvist S, Kher A, Olsson CG, et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996;76:195-9.
40. Marder VJ, Soulen RL, Atichartakarn V, Budzynski AZ, Parulekar S, Kim JR, et al. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977;89:1018-29.
41. Amesen H, Heilo A, Jakobsen E, Ly B, Skaga E. A prospective study of streptokinase and heparin in the treatment of deep vein thrombosis. Acta Med Scand 1978;203:457-63.
42. Bratt G, Törnebohm E, Granqvist S, Åberg W, Lockner D. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 1985;54:813-7.
43. Lindmarker P, Holmström M. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. J Intern Med 1996;240:395-401.
44. Cohen AT, Wagner MB, Mohamed MS. Risk factors for bleeding in major abdominal surgery using heparin thromboprophylaxis. Am J Surg 1997;174:1-5.
45. Penner JA. Managing the hemorrhagic complications of heparin therapy. Hematol Oncol Clin North Am 1993;7:1281-9.
46. Charland SL, Klinter DEJ. Low-molecular-weight heparins in the treatment of pulmonary embolism. Ann Pharmacother 1998;32:258-64.
47. Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T, et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994;72:191-7.
48. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994;71:7-11.
49. Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 1995;108(suppl 4):305S-11S.